№ lp_1_2_17165
File format: docx Character count: 47581 File size: 274 KB
A document outlining the administrative procedures for healthcare practitioners in the UK for administering the MMRV vaccine, including specific guidelines and conditions for use.
Year: 2026
Region / city: England
Topic: Vaccination
Document type: Patient Group Direction (PGD)
Organization: UK Health Security Agency (UKHSA)
Author: Christina Wilson, Dr Vanessa Saliba, David Green
Target audience: Healthcare practitioners
Validity period: 20 January 2026 – 30 November 2028
Approval date: 20 January 2026
Review date: 31 May 2028
Expiry date: 30 November 2028
Note: Change history
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Varicella vaccine (live) Patient Group Direction (PGD)
Year: 2025
Region / city: England
Topic: Immunisation, Varicella Vaccine
Document type: Patient Group Direction (PGD)
Organization / institution: UK Health Security Agency (UKHSA)
Author: Christina Wilson, Dr Vanessa Saliba, David Green
Target audience: Healthcare practitioners, Immunisation Programmes
Effective period: 5 January 2025 - 5 January 2027
Approval date: 5 January 2025
Review date: 5 July 2026
Expiry date: 5 January 2027
Version: v2.0
VARICELLA ZOSTER VIRUS RECOMBINANT VACCINE, Injection [1 vial] & adjuvant substance diluent [0.5 mL vial], Shingrix®, GlaxoSmithKline Australia Pty Ltd
Year: 2023
Region / city: Australia
Topic: Vaccination, Immunocompromised individuals, Herpes Zoster
Document type: Government recommendation
Organization: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: PBAC
Target audience: Healthcare professionals, Immunocompromised individuals
Period of validity: From November 1, 2023
Approval date: November 1, 2023
Modification date: September 2023
Measles, mumps and rubella vaccine Patient Group Direction (PGD)
Year: 2025
Region / city: England
Topic: Vaccination
Document type: Patient Group Direction (PGD)
Issuing organization: UK Health Security Agency (UKHSA)
Author: Christina Wilson, Dr. Vanessa Saliba, David Green
Target audience: Healthcare practitioners authorized to administer vaccines
Valid from: 1 January 2026
Review date: 31 May 2028
Expiry date: 30 November 2028
Version: 7.0
Date of approval: 19 December 2025
Amendments: Last amendment on 19 December 2025
Childcare Staff Documentation of Immunity to Measles, Mumps, and Rubella
Year: N/A
Region / City: N/A
Topic: Immunization Requirements for Staff in Childcare Programs
Document Type: Staff Documentation / Worksheet
Organization / Institution: EEC-regulated childcare programs
Author: N/A
Target Audience: Childcare staff responsible for maintaining immunization records
Period of Validity: N/A
Approval Date: N/A
Date of Revisions: N/A
Oral fluid kit request form for confirmation of Measles, Mumps or Rubella
Year: 20XX
Region / city: London
Topic: Measles, Mumps, Rubella
Document type: Request form
Organ / institution: UK Health Security Agency (UKHSA)
Author: Health Protection Team
Target audience: Parents/guardians of individuals suspected of having measles, mumps, or rubella
Action period: Not specified
Approval date: Not specified
Modification date: Not specified
Context: Request form for submitting oral fluid samples to confirm the presence of Measles, Mumps, or Rubella in individuals, with instructions for completing and returning the form and sample.
On March 23, 1963, Maurice Hilleman’s Response to His Daughter’s Mumps Illness
Year: 1963
Region / City: United States
Topic: Mumps, Vaccine Development
Document Type: Medical Case Study
Organization: Merck
Author: Erin Allmann Updyke, Erin Welsh
Target Audience: General Public, Medical Enthusiasts
Period of Action: March 1963
Date of Approval: N/A
Date of Changes: N/A
Note: Contextual Description
Topics: MMRV varicella mumps